Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy Ylenia IngrasciottaJanet SultanaGianluca Trifirò MEETING REPORT 16 July 2019 Pages: 345 - 352
Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Jichun YangShuqing YuFeng Sun Systematic Review 07 June 2019 Pages: 357 - 371
Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis Jichun YangShuqing YuFeng Sun Systematic Review 03 June 2019 Pages: 373 - 389
Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis Joel ReisRon VenderTiago Torres Review Article 06 June 2019 Pages: 391 - 399
Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status Alan Tyndall Review Article 13 July 2019 Pages: 401 - 409
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment Jae Hee LeeKyungyeol PaekSeokkyun Kim Original Research Article Open access 12 June 2019 Pages: 411 - 422
Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries Seung-Mi LeeJae-Ho JungDong-Churl Suh Original Research Article 14 June 2019 Pages: 423 - 436
Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development? Chien-Lung TuYi-Lin WangLi-Feng Hsu Short Communication 20 May 2019 Pages: 437 - 446
